Skip to main content
. 2013 Jul 11;13:80. doi: 10.1186/1471-2377-13-80

Figure 4.

Figure 4

Risk of cardiotoxicity with prior and/or concomitant Methotrexate therapy. Cardiac events includes patients with reported cardiac SAEs, with signs or symptoms of CHF requiring hospitalization or other therapy, with an LVEF decrease to 50% of baseline, or with a clinically significant drop in LVEF as indicated by a 10% decrease from baseline. CHF=congestive heart failure; LVEF=left ventricular ejection fraction; MTX=Methotrexate; SAE=serious adverse event.